Last updated: September 1, 2026
Elvitegravir is an HIV-1 integrase strand transfer inhibitor developed by Japan Tobacco and commercialized primarily through Gilead Sciences. Its commercial value shifted from the standalone product Vitekta to fixed-dose combinations, first Stribild and later Genvoya. Elvitegravir remains commercially relevant through Genvoya, but its growth has been constrained by Gilead’s newer Biktarvy franchise, generic pressure on older components, and the limited ability to monetize the molecule outside combination therapy.
What is elvitegravir and how is it marketed?
Elvitegravir inhibits HIV-1 integrase, an enzyme required for viral DNA integration into the host genome. It is administered with a pharmacokinetic booster because elvitegravir exposure is otherwise insufficient for once-daily dosing.
| Product |
Components |
FDA approval |
Current commercial role |
| Vitekta |
Elvitegravir |
2014 |
Standalone product; withdrawn from the U.S. market for commercial reasons |
| Stribild |
Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate |
2012 |
Older fixed-dose regimen; declining commercial importance |
| Genvoya |
Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide |
2015 |
Primary continuing elvitegravir franchise |
| Atripla and other products |
No elvitegravir |
Earlier approvals |
Competitive products, not part of the elvitegravir franchise |
Gilead developed elvitegravir under a license from Japan Tobacco. The molecule was not positioned as a durable standalone franchise. Its commercial model depended on combining it with Gilead’s nucleoside backbone and cobicistat, creating a complete once-daily HIV regimen (Gilead Sciences, 2012; Japan Tobacco, 2005).
When did elvitegravir lose exclusivity?
Elvitegravir did not lose exclusivity on a single date because the commercial products contain multiple active ingredients and rely on separate patents covering the active ingredient, combinations, formulations, and methods of treatment.
The key commercial sequence was:
- 2012: FDA approves Stribild.
- 2014: FDA approves Vitekta.
- 2015: FDA approves Genvoya.
- 2017: Gilead discontinues Vitekta in the United States for commercial reasons.
- Late 2020s: principal composition and combination patent barriers begin to weaken, depending on the product and patent listing.
- Early 2030s: some later-filed Genvoya formulation and combination patents may extend protection beyond the earliest elvitegravir patents, subject to patent-term adjustments, pediatric extensions, terminal disclaimers, and litigation outcomes.
A precise generic-entry date must be assessed at the product level. The expiration of an elvitegravir compound patent does not automatically authorize a generic version of Genvoya, which may remain exposed to patents covering the full combination or its formulation.
What is the Orange Book status of elvitegravir products?
Stribild and Genvoya have been listed in the FDA Orange Book with patents directed to drug substances, drug products, fixed-dose combinations, formulations, and methods of use. The Orange Book is the relevant source for determining which patents a generic applicant must address in an Abbreviated New Drug Application.
The key distinction is between:
- Elvitegravir compound patents, which protect the active ingredient.
- Combination patents, which protect elvitegravir with cobicistat and the nucleoside backbone.
- Formulation patents, which cover tablet composition, stability, and delivery.
- Method-of-use patents, which cover treatment of HIV infection or particular patient populations.
- Tenofovir alafenamide patents, which may create an independent barrier to Genvoya even after elvitegravir protection weakens.
The Orange Book status is product-specific. Vitekta’s withdrawal from sale does not eliminate the historical patent record, while Stribild and Genvoya remain the more relevant products for generic-entry analysis (U.S. Food and Drug Administration, 2024).
What formulations are protected by elvitegravir patents?
Genvoya is a low-dose, fixed-dose tablet containing:
- Elvitegravir
- Cobicistat
- Emtricitabine
- Tenofovir alafenamide
The formulation replaces tenofovir disoproxil fumarate in Stribild with tenofovir alafenamide. That change reduced tenofovir plasma exposure and improved renal and bone safety relative to the earlier regimen, but it also created a separate patent and regulatory profile (Gilead Sciences, 2015).
The formulation value lies less in elvitegravir alone than in the combination’s dose ratio, tablet architecture, stability, bioavailability, and compatibility with cobicistat. These features can make a formulation patent commercially relevant after basic compound claims expire.
How did elvitegravir revenue develop?
Gilead does not generally report revenue for elvitegravir as a standalone molecule. It reports sales by branded product, while Genvoya and Stribild revenue includes the value of all active ingredients and the complete regimen. Financial analysis therefore requires a product-level attribution rather than a pure molecule-level estimate.
Product revenue trajectory
| Period |
Commercial pattern |
Financial interpretation |
| 2012-2014 |
Stribild launch and Vitekta approval |
Rapid uptake of once-daily integrase-based therapy |
| 2015-2017 |
Genvoya launch and conversion from Stribild |
Revenue migration toward the TAF-based product |
| 2018-2020 |
Genvoya maturation |
High-value maintenance franchise, supported by safety and convenience |
| 2021 onward |
Biktarvy expansion |
Increasing cannibalization and reduced strategic priority for elvitegravir |
| Late 2020s onward |
Patent and generic pressure |
Declining pricing power and possible volume erosion |
Genvoya became a major Gilead HIV product. Gilead reported approximately $3 billion or more in annual Genvoya sales during the mature period of the franchise, although the exact figure varied by year and geographic accounting. Stribild sales declined as prescribers and patients moved to Genvoya and newer regimens. Gilead’s HIV portfolio remained a multibillion-dollar business, but elvitegravir represented only part of that revenue and was not separately disclosed (Gilead Sciences, 2016, 2018, 2020, 2022).
The most important financial event was not generic entry. It was internal substitution by Biktarvy, which contains bictegravir rather than elvitegravir and does not require cobicistat boosting. Biktarvy offered a simpler regimen with strong efficacy and a cleaner interaction profile, allowing Gilead to retain HIV revenue while moving demand to a newer product (Gilead Sciences, 2018; FDA, 2018).
How does elvitegravir compare with bictegravir and dolutegravir?
| Attribute |
Elvitegravir |
Bictegravir |
Dolutegravir |
| Representative product |
Genvoya |
Biktarvy |
Tivicay, Triumeq, Dovato |
| Booster required |
Yes, cobicistat |
No |
No |
| Main commercial sponsor |
Gilead |
Gilead |
ViiV Healthcare |
| Fixed-dose positioning |
Genvoya |
Biktarvy |
Multiple combinations |
| Drug-interaction burden |
Higher because of cobicistat |
Lower than elvitegravir |
Generally lower than boosted regimens |
| Commercial trajectory |
Mature and declining |
Growth and portfolio leader |
Durable competitor |
| Biosimilar exposure |
None |
None |
None |
| Generic exposure |
Increasing over time |
Later-stage exposure |
Increasing over time |
Bictegravir has a structural commercial advantage because it eliminates the need for cobicistat. Cobicistat creates clinically relevant drug-interaction considerations and requires more careful medication management. Dolutegravir also competes strongly because of its unboosted dosing, broad guideline adoption, and presence in lower-cost global treatment programs.
Elvitegravir remains clinically useful, particularly where Genvoya is established and covered by reimbursement systems. Its competitive position is weaker in new starts because prescribers increasingly favor unboosted integrase inhibitors.
What generic entry risks exist for elvitegravir?
Elvitegravir faces conventional small-molecule generic risk rather than biosimilar risk. The most likely entry sequence is:
- Generic versions of individual components or older products.
- Generic Stribild-equivalent products after relevant product and method patents expire or are successfully challenged.
- Generic Genvoya-equivalent products after patents covering tenofovir alafenamide combinations and formulation barriers weaken.
- Price erosion in payer channels, followed by substitution in treatment guidelines and formularies.
Generic entry would not necessarily eliminate Genvoya sales immediately. HIV products often remain differentiated by formulary placement, patient stability, physician familiarity, co-pay support, and procurement contracts. The effect would be greater where generic substitution is automatic and lower where branded combination products retain preferred coverage.
Which companies are challenging elvitegravir patents?
Publicly visible generic competition has focused more broadly on Gilead’s HIV product portfolio than on a single elvitegravir compound patent. Potential challengers include large generic manufacturers with experience in antiretroviral products, such as Teva, Mylan/Viatris, Sandoz, Cipla, and Indian manufacturers supplying international markets.
A Paragraph IV filing is product-specific and can change as applicants file ANDAs, settle disputes, or receive tentative or final approval. The relevant litigation question is whether a challenger targets Stribild, Genvoya, or an individual component. A challenge to an elvitegravir compound patent may not defeat separate patents covering Genvoya’s complete combination.
What patent litigation affects elvitegravir products?
Elvitegravir-related risk sits within Gilead’s broader HIV patent litigation environment. The most commercially material disputes have often involved tenofovir, tenofovir alafenamide, fixed-dose combinations, and pediatric or formulation claims rather than elvitegravir alone.
The main litigation variables are:
- Whether a generic applicant files a Paragraph IV certification.
- Whether Gilead sues within the statutory 45-day period.
- Whether the case triggers a 30-month FDA approval stay.
- Whether the parties settle with a negotiated launch date.
- Whether the court upholds composition or formulation claims.
- Whether a generic can launch at risk before final judgment.
- Whether an authorized generic or license changes price competition.
No broad biosimilar litigation pathway applies because elvitegravir is a chemically synthesized small molecule. Patent litigation remains the primary legal mechanism for delaying or accelerating generic entry.
Has Gilead licensed elvitegravir?
Yes. Japan Tobacco discovered elvitegravir and licensed development and commercialization rights to Gilead. The transaction gave Gilead access to an integrase inhibitor that became part of its single-tablet HIV strategy. Gilead later retained control over the principal branded combinations, while Japan Tobacco remained associated with the underlying intellectual-property origin of the molecule (Japan Tobacco, 2005).
The licensing structure matters for economics. Royalty or milestone obligations can reduce the net margin attributable to elvitegravir, but Gilead’s larger value capture came from the complete regimen, manufacturing platform, regulatory approvals, global distribution, and lifecycle management.
What geographic coverage does elvitegravir have?
Genvoya and Stribild obtained approvals in major regulated markets, including the United States and Europe. Market durability varies by region:
- United States: High branded value historically, with strong exposure to Orange Book patents and commercial formulary decisions.
- Europe: National reimbursement and tender systems create greater price pressure.
- Emerging markets: Lower net prices, public procurement, and broader use of alternative integrase inhibitors reduce the value of elvitegravir-based products.
- Low-income markets: Dolutegravir-based regimens have become particularly important because of cost, dosing, and global-access programs.
Geographic patent coverage also varies. U.S. and European patent positions may not predict enforceability or commercial exclusivity in India, Brazil, China, or other markets. Local compulsory-license rules, national phase filings, patent validity standards, and government procurement policies affect the effective market barrier.
How strong is the elvitegravir patent estate?
The estate is moderately strong for the branded combination but weaker as a standalone molecule.
Strengths
- Multiple layers of protection across compound, combination, formulation, and method claims.
- Genvoya’s later approval created a newer product-specific patent position than Stribild.
- Fixed-dose formulation complexity can increase generic development and bioequivalence risk.
- Cobicistat and tenofovir alafenamide create additional combination dependencies.
Weaknesses
- Elvitegravir is an older integrase inhibitor.
- Standalone Vitekta failed to establish durable commercial demand.
- Genvoya faces substitution by Biktarvy, an internally competing Gilead product.
- Generic applicants can target individual products or challenge selected patents rather than the entire estate.
- The product’s dependence on cobicistat reduces its attractiveness for new prescriptions.
The estate is therefore more effective at delaying direct Genvoya substitution than at sustaining elvitegravir as an independent growth platform.
What is the financial outlook for elvitegravir?
The financial trajectory is mature-to-declining. Genvoya can continue generating substantial revenue because HIV treatment is chronic, adherence is valuable, and patients often remain on stable regimens. However, three forces limit future growth:
- Biktarvy captures new and switching patients.
- Generic or authorized-generic competition pressures older products.
- Payers increasingly favor unboosted integrase inhibitor regimens.
The likely outcome is a long-tail revenue profile rather than an abrupt collapse. Revenue will decline through reduced new starts, formulary repricing, and eventual generic substitution. The product may retain residual value in stable patients, specific reimbursement channels, and markets where Genvoya remains clinically or economically preferred.
Key Takeaways
- Elvitegravir is commercially important mainly through Genvoya, not Vitekta.
- Stribild established the franchise, but Genvoya became the principal branded product.
- Gilead does not disclose molecule-level elvitegravir revenue; reported sales are product-based.
- Biktarvy is the largest strategic threat because it is an unboosted, newer integrase-inhibitor regimen from the same company.
- Generic risk is higher for Stribild and older products and becomes more material for Genvoya as combination and formulation patents expire.
- Elvitegravir has no biosimilar risk because it is a small molecule.
- The patent estate is layered but product-specific. An expired compound patent would not necessarily permit immediate Genvoya entry.
- The commercial outlook is a gradual decline, with continued residual revenue from chronic-treatment persistence.
FAQs About Elvitegravir Market and Patent Risk
Is elvitegravir still sold as a standalone drug?
No. Vitekta was withdrawn from the U.S. market for commercial reasons. Elvitegravir remains available primarily in the fixed-dose combination Genvoya.
Is Genvoya a biologic or a small-molecule drug?
Genvoya is a small-molecule combination product. Generic applicants file ANDAs, not biosimilar applications.
Does Biktarvy contain elvitegravir?
No. Biktarvy contains bictegravir, emtricitabine, and tenofovir alafenamide. It does not contain elvitegravir or cobicistat.
Can a generic company market elvitegravir alone?
A company may seek approval for a standalone elvitegravir product if it can satisfy regulatory, formulation, and patent requirements. Commercial demand is limited because elvitegravir normally requires pharmacokinetic boosting and is most useful within a complete antiretroviral regimen.
What is the largest commercial risk to Genvoya?
The largest near-term risk is product substitution by Biktarvy. The largest later-stage risk is generic entry after the remaining Genvoya combination, formulation, and method-of-use barriers no longer prevent approval or launch.
References
-
Gilead Sciences, Inc. (2012). Stribild prescribing information. U.S. Food and Drug Administration.
-
Gilead Sciences, Inc. (2015). Genvoya prescribing information. U.S. Food and Drug Administration.
-
Gilead Sciences, Inc. (2016). 2015 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2018). 2017 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2020). 2019 annual report. Gilead Sciences.
-
Gilead Sciences, Inc. (2022). 2021 annual report. Gilead Sciences.
-
Japan Tobacco Inc. (2005). Japan Tobacco and Gilead Sciences enter licensing agreement for HIV integrase inhibitor. Japan Tobacco.
-
U.S. Food and Drug Administration. (2018). Biktarvy approval letter and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
